ARVN•benzinga•
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
Summary
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 6, 2025 by benzinga